Clinical trial
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid…
NCT00476996 · Genentech, Inc., Industry · Terminated
Key facts
| NCT number | NCT00476996 |
|---|---|
| Title | A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT) |
| Official title | A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-α Therapy |
| Acronym | SCRIPT |
| Lead sponsor | Genentech, Inc., Industry |
| Collaborators | Roche Pharma AG Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Leflunomide, Methotrexate, Ocrelizumab, Placebo |
| Enrollment | 836 |
| Start date | May 15, 2007 |
| Primary completion | Jan 21, 2010 |
| Completion | May 14, 2018 |
| First posted | May 22, 2007 |
| Last update posted | Aug 12, 2019 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Japan and 13 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: